First Horizon Advisors Inc. Cuts Stake in Johnson & Johnson (NYSE:JNJ)

First Horizon Advisors Inc. decreased its holdings in Johnson & Johnson (NYSE:JNJ) by 2.4% in the fourth quarter, Holdings Channel reports. The firm owned 253,067 shares of the company’s stock after selling 6,099 shares during the quarter. Johnson & Johnson accounts for about 1.0% of First Horizon Advisors Inc.’s portfolio, making the stock its 20th biggest position. First Horizon Advisors Inc.’s holdings in Johnson & Johnson were worth $36,599,000 at the end of the most recent quarter.

A number of other hedge funds have also bought and sold shares of JNJ. Lipe & Dalton grew its position in shares of Johnson & Johnson by 2.1% during the 4th quarter. Lipe & Dalton now owns 9,657 shares of the company’s stock valued at $1,397,000 after acquiring an additional 202 shares during the period. Capital City Trust Co. FL grew its holdings in Johnson & Johnson by 1.4% during the fourth quarter. Capital City Trust Co. FL now owns 41,129 shares of the company’s stock valued at $5,948,000 after purchasing an additional 567 shares during the period. Redmond Asset Management LLC lifted its position in shares of Johnson & Johnson by 67.5% during the 4th quarter. Redmond Asset Management LLC now owns 56,990 shares of the company’s stock valued at $8,242,000 after buying an additional 22,972 shares in the last quarter. SAM Advisors LLC grew its stake in shares of Johnson & Johnson by 2.9% during the 4th quarter. SAM Advisors LLC now owns 12,033 shares of the company’s stock valued at $1,740,000 after acquiring an additional 338 shares during the period. Finally, Oxbow Advisors LLC increased its holdings in Johnson & Johnson by 0.5% in the 4th quarter. Oxbow Advisors LLC now owns 41,536 shares of the company’s stock worth $6,007,000 after acquiring an additional 213 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Up 1.5 %

Shares of NYSE JNJ opened at $166.13 on Wednesday. The business’s 50 day moving average price is $149.72 and its 200-day moving average price is $155.92. Johnson & Johnson has a fifty-two week low of $140.68 and a fifty-two week high of $168.85. The company has a debt-to-equity ratio of 0.43, a quick ratio of 0.86 and a current ratio of 1.11. The company has a market cap of $399.98 billion, a price-to-earnings ratio of 24.98, a PEG ratio of 2.56 and a beta of 0.52.

Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Wednesday, January 22nd. The company reported $2.04 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.99 by $0.05. The firm had revenue of $22.52 billion during the quarter, compared to analyst estimates of $22.44 billion. Johnson & Johnson had a net margin of 18.20% and a return on equity of 34.24%. The business’s revenue was up 5.3% on a year-over-year basis. During the same period in the previous year, the firm earned $2.29 earnings per share. On average, sell-side analysts expect that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 4th. Stockholders of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. This represents a $4.96 annualized dividend and a dividend yield of 2.99%. The ex-dividend date is Tuesday, February 18th. Johnson & Johnson’s dividend payout ratio is presently 74.59%.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on JNJ shares. Argus upgraded shares of Johnson & Johnson to a “strong-buy” rating in a research report on Friday, January 24th. Morgan Stanley dropped their target price on shares of Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a report on Thursday, January 23rd. Wells Fargo & Company decreased their price target on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a report on Thursday, January 23rd. Bank of America dropped their price objective on Johnson & Johnson from $160.00 to $159.00 and set a “neutral” rating for the company in a research note on Thursday, January 23rd. Finally, Guggenheim lifted their target price on Johnson & Johnson from $162.00 to $166.00 and gave the company a “neutral” rating in a research note on Monday, February 3rd. Nine research analysts have rated the stock with a hold rating, eight have assigned a buy rating and two have given a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $170.67.

Insider Buying and Selling

In other Johnson & Johnson news, EVP Timothy Schmid sold 403 shares of the stock in a transaction dated Tuesday, February 18th. The shares were sold at an average price of $156.15, for a total transaction of $62,928.45. Following the transaction, the executive vice president now directly owns 15,098 shares in the company, valued at $2,357,552.70. This represents a 2.60 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Mark A. Weinberger purchased 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was acquired at an average price of $147.22 per share, with a total value of $147,220.00. Following the acquisition, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The disclosure for this purchase can be found here. 0.16% of the stock is owned by insiders.

Johnson & Johnson Profile

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.